At a glance
ClinicalIndex Comparison RecordN/ACompleted· 30 enrolled
Drug / intervention
Beclin 1 genegenetic
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Investigation of Autophagy Markers in Endometrial Polyps
In Brief
An observational study evaluating Beclin 1 gene for Endometrial Polyp and Autophagy. Completed, enrolled 30 participants across 1 site.
Detailed Summary
The aim of this research is to evaluate autophagy markers in patients with endometrial polyps
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsEndometrial Polyp, Autophagy
CountriesTurkey (Türkiye)
Collaborators--
Timeline
N/ACompletedFinished
202120222023202420252026
Enrollment StartJan 2021
First PostedJan 2021
Primary CompletionJan 2022
Study CompletionFeb 2022
TodayJul 2026
First PostedJan 12, 2021
Enrollment StartJan 8, 2021
Primary CompletionJan 8, 2022
Study CompletionFeb 1, 2022
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 5.5 years ago
Interventions
Beclin 1 genegenetic
The determination of Beclin 1, LC3-II and p62 genes, which are evaluated by immunohistochemistry, at the protein level will be done by ELISA method in MSKU Medical Faculty Medical Biology Laboratory.